Orthocell Limited announced a research collaboration agreement with DePuy Synthes Products Inc., part of the Johnson & Johnson Family of Companies, on its Ortho-ATI stem cell approach to regenerate degenerated tendons and ligaments. According to a press release, the partnership was facilitated by Johnson & Johnson Innovation.
Ortho-ATI is a non-surgical approach to treat chronic resistant tendon injuries that significantly impact activities of daily living. Ortho-ATI is offered in Australia and New Zealand for patients who have failed conservative treatment options and have ongoing symptoms. A collaborative, multicenter study on the approach is set to begin in the first quarter of 2017.
“This is [an] exciting partnership in the continued development of Ortho-ATI and provides significant external validation of this globally relevant technology,” Paul Anderson, managing director, said in the release.